- Gilead’s Phase 2 EVOKE-02 Study of Trodelvy in Combination with KEYTRUDA demonstrates promising clinical activity in first-line metastatic non-small cell lung cancer, indicating potential growth opportunities.
- Gilead Sciences has a high institutional ownership of 86%, suggesting confidence from major investors.
- The FDA approval for Veklury to treat COVID-19 in people with hepatic impairment is a positive development for Gilead’s product portfolio.
- The clinical hold for Magrolimab studies in AML and the leukemia study progress put on clinical hold may pose challenges for Gilead’s pipeline.
- Market volatility and competition in the healthcare and pharmaceutical industry can affect Gilead’s stock performance.
- Gilead Sciences’ stock experienced a significant single-day move recently, which may raise concerns about short-term volatility.
investment score = chances characters count - risks characters count
- 2023-09-10 Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
- 2023-09-09 Only Four Days Left To Cash In On Gilead Sciences’ (NASDAQ:GILD) Dividend
- 2023-09-09 The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
- 2023-09-09 US STOCKS-S&P 500 closes up slightly ahead of US inflation data
- 2023-09-09 US STOCKS-Wall St rises as megacaps gain, yields slip ahead of US inflation data
- 2023-09-09 US STOCKS-Wall St rises as megacaps gain, yields slip ahead of key inflation data
- 2023-09-08 Unveiling Gilead Sciences (GILD)’s Value: Is It Really Priced Right? A Comprehensive Guide
- 2023-09-08 Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts
- 2023-09-08 Adobe upgraded, DigitalOcean double downgraded: Wall Street’s top analyst calls
- 2023-09-08 Gilead Prices $2 Billion of Senior Unsecured Notes